Cargando…

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial

BACKGROUND: The use of IL-6 blockers in COVID-19 hospitalized patients has been associated with a reduction in mortality compared to standard care. However, many uncertainties remain pertaining to optimal intervention time, administration schedule, and predictors of response. To date, data on the us...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Vicuña, Rosario, Rodriguez-García, Sebastián C., Abad-Santos, Francisco, Bautista Hernández, Azucena, García-Fraile, Lucio, Barrios Blandino, Ana, Gutiérrez Liarte, Angela, Alonso-Pérez, Tamara, Cardeñoso, Laura, Alfranca, Aránzazu, Mejía-Abril, Gina, Sanz Sanz, Jesús, González-Alvaro, Isidoro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904894/ https://www.ncbi.nlm.nih.gov/pubmed/35280907 http://dx.doi.org/10.3389/fmed.2022.819621

Ejemplares similares

Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
por: Garcia-Vicuña, Rosario, et al.
Publicado: (2020)

Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs
por: Uriarte Ecenarro, Miren, et al.
Publicado: (2022)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Anti-citrullinated protein antibodies and bone loss in patients with early arthritis: comment on the article “Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis” by Bugatti et al.
por: Castañeda, Santos, et al.
Publicado: (2017)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Sarilumab: Cytomegalovirus colitis: case report
Publicado: (2020)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Sarilumab: Perforated duodenal ulcer: case report
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
por: Paccaly, Anne J., et al.
Publicado: (2020)

Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
por: Branch-Elliman, Westyn, et al.
Publicado: (2022)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Ambulatory Blood Pressure Monitoring in HIV-Infected Patients: Usefulness for Cardiovascular Risk Assessment
por: Gómez-Berrocal, Ana, et al.
Publicado: (2020)

The Minor Allele of rs7574865 in the STAT4 Gene Is Associated with Increased mRNA and Protein Expression
por: Lamana, Amalia, et al.
Publicado: (2015)

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
por: Galván-Román, José María, et al.
Publicado: (2021)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

Sarilumab use in severe SARS-CoV-2 pneumonia
por: Gremese, Elisa, et al.
Publicado: (2020)

Sarilumab: Thrombocytopenia during an off-label use: case report
Publicado: (2020)

Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
por: Chamlagain, Rajan, et al.
Publicado: (2021)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients
por: Llorente, Irene, et al.
Publicado: (2017)

517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
por: Branch-Elliman, Westyn, et al.
Publicado: (2021)

Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity
por: Villapalos-García, Gonzalo, et al.
Publicado: (2022)

Correction: Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity and sex are the primary predictors of Covid-19 severity
por: Villapalos-García, Gonzalo, et al.
Publicado: (2022)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
por: Mejía-Abril, Gina, et al.
Publicado: (2021)

A physical activity program versus usual care in the management of quality of life for pre-frail older adults with chronic pain: randomized controlled trial
por: Otones, Pedro, et al.
Publicado: (2020)

Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study)
por: Sancho-López, Aránzazu, et al.
Publicado: (2021)

Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis
por: Martínez, Carmen, et al.
Publicado: (2014)

Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity
por: Seoane, Iria V., et al.
Publicado: (2016)

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients
por: González-Álvaro, Isidoro, et al.
Publicado: (2017)

PTGDR gene expression and response to dexamethasone treatment in an in vitro model
por: Marcos-Vadillo, Elena, et al.
Publicado: (2017)

Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
por: Cingolani, A., et al.
Publicado: (2020)

Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis
por: Seoane, Iria V., et al.
Publicado: (2018)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Initial clinical outcomes and prognostic variables in the implementation of a Code Sepsis in a high complexity University Hospital
por: Ramasco, Fernando, et al.
Publicado: (2019)

Componentes y operacion del motor de combustion interna a Diesel /
por: Garcia Neblina, Lucio Isidoro
Publicado: (2004)

Low P-Selectin Glycoprotein Ligand-1 Expression in Neutrophils Associates with Disease Activity and Deregulated NET Formation in Systemic Lupus Erythematosus
por: Muñoz-Callejas, Antonio, et al.
Publicado: (2023)

PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_13ql155u63plbttm3jds44087q